Bernhard Landwehrmeyer

Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients (2009)

Pfister, Edith L., Kennington, Lori A., Straubhaar, Juerg R., Wagh, Sujata, Liu, Wanzhou, DiFiglia, Marian, ...

Among dominant neurodegenerative disorders, Huntington's disease (HD) is perhaps the best candidate for treatment with small interfering RNAs (siRNAs) [1-9]. Invariably fatal, HD is caused by...

Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. (2007)

Björkqvist, Maria, Leavitt, Blair R, Nielsen, Jörgen E, Landwehrmeyer, Bernhard, Ecker, Daniel, Mulder, Hindrik, ...

Abstract is not available

Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease (2005)

Saft, Carsten, Zange, Jochen, Andrich, Jürgen, Müller, Klaus, Lindenberg, Katrin, Landwehrmeyer, Bernhard, ...

Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the IT-15 gene; however, it remains unknown how the mutation leads to...

Transgenic rat model of Huntington's disease (2003)

Von Hörsten, Stephan, Schmitt, Ina, Nguyen, Huu Phuc, Holzmann, Carsten, Schmidt, Thorsten, Walther, Thomas, ...

Huntington's disease (HD) is a late manifesting neurodegenerative disorder in humans caused by an expansion of a CAG trinucleotide repeat of more than 39 units in a gene of unknown function. Several...

Impaired Regulation of Brain Mitochondria by Extramitochondrial Ca2+ in Transgenic Huntington Disease Rats*

Gellerich, Frank N., Gizatullina, Zemfira, Nguyen, Huu P., Trumbeckaite, Sonata, Vielhaber, Stefan, Seppet, Enn, ...

Huntington disease (HD) is characterized by polyglutamine expansions of huntingtin (htt), but the underlying pathomechanisms have remained unclear. We studied brain mitochondria of transgenic HD rats...